- Home
- PHK vs TYRA Comparison
PHK vs TYRA Comparison
Compare PHK & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- TYRA
- Stock Information
- Founded
- PHK 2003
- TYRA 2018
- Country
- PHK United States
- TYRA United States
- Employees
- PHK N/A
- TYRA N/A
- Industry
- PHK Finance/Investors Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- PHK Finance
- TYRA Health Care
- Exchange
- PHK Nasdaq
- TYRA Nasdaq
- Market Cap
- PHK 777.7M
- TYRA 812.7M
- IPO Year
- PHK N/A
- TYRA 2021
- Fundamental
- Price
- PHK $4.87
- TYRA $14.00
- Analyst Decision
- PHK
- TYRA Strong Buy
- Analyst Count
- PHK 0
- TYRA 5
- Target Price
- PHK N/A
- TYRA $31.00
- AVG Volume (30 Days)
- PHK 491.5K
- TYRA 219.5K
- Earning Date
- PHK 01-01-0001
- TYRA 11-07-2024
- Dividend Yield
- PHK 12.61%
- TYRA N/A
- EPS Growth
- PHK N/A
- TYRA N/A
- EPS
- PHK N/A
- TYRA N/A
- Revenue
- PHK N/A
- TYRA N/A
- Revenue This Year
- PHK N/A
- TYRA N/A
- Revenue Next Year
- PHK N/A
- TYRA N/A
- P/E Ratio
- PHK N/A
- TYRA N/A
- Revenue Growth
- PHK N/A
- TYRA N/A
- 52 Week Low
- PHK $4.13
- TYRA $11.24
- 52 Week High
- PHK $5.15
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- PHK 30.39
- TYRA 32.68
- Support Level
- PHK $4.81
- TYRA $14.65
- Resistance Level
- PHK $5.09
- TYRA $15.55
- Average True Range (ATR)
- PHK 0.05
- TYRA 0.72
- MACD
- PHK -0.02
- TYRA 0.02
- Stochastic Oscillator
- PHK 22.14
- TYRA 3.12
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).